TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations.
Ezra Y RosenDebra A GoldmanJaclyn F HechtmanRyma BenayedAlison M SchramEmiliano CoccoSophie ShifmanYixiao GongRitika KundraJames P SolomonAlberto BardelliMaurizio ScaltritiAlexander E DrilonAlexia IasonosBarry S TaylorDavid M HymanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
TRK fusion-positive cancers can respond to alternative standards of care, although efficacy of immunotherapy in the absence of other predictive biomarkers (MSI-H) appears limited. TRK fusions are present in tumors with simple genomes lacking in concurrent drivers that may partially explain the tumor-agnostic efficacy of TRK inhibitors.